News|Articles|October 14, 2026

A New Approach to Clinical Trial Planning: How Mid-Market and Emerging Pharma Can Take Greater Control of Patient Enrollment

This executive summary looks at how mid-size and emerging pharma companies can keep greater control of patient enrollment by treating site selection, timeline forecasting, and in-study adaptation as one connected process. Using an illustrative Phase 3 ALK-positive non–small cell lung cancer (NSCLC) trial and a representative five-study portfolio, it shows how the ZAIDYN clinical platform supports each decision with shared, evidence-based data.


Related to this article

© putilov_denis - © putilov_denis - stock.adobe.com
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.